Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

870487.pdf (1.16 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-12-15

Llicència de publicació

cc-by-nc-nd (c) Rodriguez-Tajes, Sergio et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/218050

The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/liv.15777

Resum

Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.

Matèries

Hepatitis B, Trasplantament hepàtic, Virus de l'hepatitis delta

Matèries (anglès)

Hepatitis B, Hepatic transplantation, Delta-associated agent

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

RODRIGUEZ-TAJES, Sergio, et al. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis. Liver International. 2023. Vol. 44, num. 2, pags. 279-285. ISSN 1478-3223. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/218050

Exportar metadades

JSON - METS

Compartir registre